Guest post by C Blease
Talking cures have never been so accessible. Since 2007 the UK government has invested £300 million launching its Improved Access to Psychological Treatments scheme. The goal is to train up to 4000 therapists in a particular branch of psychotherapy – cognitive behavioural therapy (CBT). CBT is the most widely researched and most commonly used “talking therapy” in the world. It is also on the rise: globally, a quarter of all practicing therapists use it.
The UK government’s decision to invest in CBT seems praiseworthy: as Bob Hoskins used to counsel in the old BT adverts, “It’s good to talk”. It is certainly a sentiment shared by the British Association for Counselling and Psychotherapy (BACP) – which adopts the familiar tag line for its URL (www.itsgoodtotalk.org.uk).
On the face of it, this seems like good advice. Even a cursory look at the evidence base is encouraging. Meta-analyses show that around 80 per cent of people who undergo psychotherapy for the treatment of depression are better off than those who receive no treatments. They are also significantly less likely to relapse than those treated with antidepressants; some evidence even indicates that psychotherapy acts as a prophylactic, preventing future lapses into depression. Given that the WHO estimates that depression will be the leading cause of disability in the world by 2020, the health benefits of psychotherapy carry enormous promise. The potential relative healthcare costs of successfully treating (and preventing) depression with psychotherapy are significant too: in the UK depression incurs annual costs in lost earnings of £11 billion annually, and prescription rates for antidepressants are now at an all-time high.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.